Ultragenyx Pharmaceutical (RARE) Other Gross PP&E Adjustments (2016 - 2025)
Ultragenyx Pharmaceutical (RARE) has disclosed Other Gross PP&E Adjustments for 10 consecutive years, with $380.0 million as the latest value for Q4 2025.
- On a quarterly basis, Other Gross PP&E Adjustments rose 0.53% to $380.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was $380.0 million, a 0.53% increase, with the full-year FY2025 number at $380.0 million, up 0.53% from a year prior.
- Other Gross PP&E Adjustments was $380.0 million for Q4 2025 at Ultragenyx Pharmaceutical, up from $378.0 million in the prior quarter.
- In the past five years, Other Gross PP&E Adjustments ranged from a high of $380.0 million in Q4 2025 to a low of -$38.6 million in Q2 2021.
- A 5-year average of $93.6 million and a median of -$24.7 million in 2023 define the central range for Other Gross PP&E Adjustments.
- Biggest YoY gain for Other Gross PP&E Adjustments was 122.14% in 2021; the steepest drop was 7.49% in 2021.
- Ultragenyx Pharmaceutical's Other Gross PP&E Adjustments stood at $156.3 million in 2021, then skyrocketed by 90.05% to $297.1 million in 2022, then increased by 25.85% to $374.0 million in 2023, then rose by 1.08% to $378.0 million in 2024, then grew by 0.53% to $380.0 million in 2025.
- Per Business Quant, the three most recent readings for RARE's Other Gross PP&E Adjustments are $380.0 million (Q4 2025), $378.0 million (Q4 2024), and $374.0 million (Q4 2023).